Sphingosine 1-phosphate receptor modulator, fingolimod (FTY720), provides a new therapeutic approach for autoimmune diseases
スポンサーリンク
概要
- 論文の詳細を見る
- 2010-09-25
著者
-
Sugahara Kunio
Pharmacology Research Laboratories I Research Division Mitsubishi Tanabe Pharma Corporation
-
Chiba Kenji
Pharmacology Research Laboratories I Research Division Mitsubishi Tanabe Pharma Corporation
-
Maeda Yasuhiro
Pharmacology Research Laboratories I Research Division Mitsubishi Tanabe Pharma Corporation
-
KATAOKA Hirotoshi
Pharmacology Research Laboratories I, Research Division, Mitsubishi Tanabe Pharma Corporation
-
Seki Noriyasu
Pharmacology Research Laboratories I Research Division Mitsubishi Tanabe Pharma Corporation
-
Kataoka Hirotoshi
Pharmacology Research Laboratories I Research Division Mitsubishi Tanabe Pharma Corporation
関連論文
- FTY720 induces the sequestration of circulating lymphocytes into the bone marrow in alymphoplasia mice
- Fingolimod (FTY720) ameliorates experimental autoimmune encephalomyelitis (EAE) (2) FTY720 decreases infiltration of Th17 and Th1 cells into the central nervous system in EAE
- Sphingosine 1-phosphate receptor modulator, fingolimod (FTY720), provides a new therapeutic approach for autoimmune diseases
- Sphingosine 1-phosphate receptor type 1 as a novel target for the therapy of autoimmune diseases
- Fingolimod (FTY720) ameliorates experimental autoimmune encephalomyelitis (EAE) : II. FTY720 decreases infiltration of Th17 and Th1 cells into the central nervous system in EAE
- Fingolimod (FTY720) ameliorates experimental autoimmune encephalomyelitis (EAE) : I. Oral administration of FTY720 effectively inhibits relapse of EAE
- Sphingosine 1-phosphate receptor modulator, fingolimod (FTY720), provides a new therapeutic approach for autoimmune diseases
- Sphingosine 1-phosphate receptor type 1 regulates egress of mature T cells from mouse bone marrow